findmyKOL
Clinical trialNCT02793544CompletedPhase 2Interventional

HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide

SponsorCenter for International Blood and Marrow Transplant ResearchEnrollment80Acute Biphenotypic Leukemia (ABL)Acute Lymphoblastic Leukemia (ALL)/T Lymphoblastic LymphomaAcute Myelogenous Leukemia (AML)Acute Undifferentiated Leukemia (AUL)Chemotherapy-sensitive LymphomaChronic Lymphocytic Leukemia (CLL)+1 more conditions
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a multi-center, single arm Phase II study of hematopoietic cell transplantation (HCT) using human leukocyte antigen (HLA)-mismatched unrelated bone marrow transplantation donors and post-transplantation cyclophosphamide (PTCy), sirolimus and mycophenolate mofetil (MMF) for graft versus host disease (GVHD) prophylaxis in patients with hematologic malignancies.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

11 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Shands Healthcare & University of Florida

    Gainesville, Florida, United States

  • University of Miami

    Miami, Florida, United States

  • H. Lee Moffitt Cancer Center and Research Institute

    Tampa, Florida, United States

  • the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    Baltimore, Maryland, United States

  • University of Maryland Greenebaum Cancer Center

    Baltimore, Maryland, United States

  • Karmanos Cancer Institute

    Detroit, Michigan, United States

  • Memorial Sloan Kettering Cancer Center - Adults

    New York, New York, United States

  • University of North Carolina Hospitals

    Chapel Hill, North Carolina, United States

  • Ohio State Medical Center, James Cancer Center

    Columbus, Ohio, United States

  • Virginia Commonwealth University Massey Cancer Center Bone Marrow Transplant Program

    Richmond, Virginia, United States

  • Froedtert Memorial Lutheran Hospital

    Milwaukee, Wisconsin, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Busulfan →Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5Cyclophosphamide →Fludarabine →G-CSF →Mycophenolate mofetil →Post-HCT Cyclophosphamide 50mg/kg IV on Day+3, +4Post-HCT MesnaPre-HCT Mesna on Days -2 and -1Pre-HCT Mesna on Days -5 and -4Pre-HCT Mesna on Days -6 and -5Sirolimus →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 Dec 2016
Primary completion
31 Mar 2020
Completion
31 Mar 2020
Last update posted
6 Aug 2025
Registered enrollment
80
Registry id
NCT02793544
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.